Floatz logo

Daunorubicin

Acute Leukaemia

Novartis PharmaceuticalsPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

60 Active assets in the Acute Leukaemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Sawa Ito, MD
Phase 2/3BB
Cyclophosphamide
Sawa Ito, MD
Phase 4BB
Cytosin-Arabinosid
Janssen Research & Development, LLC
Phase 2/3BB
Busulphan
Sawa Ito, MD
Phase 4BB
ETOPOSIDE
Nanfang Hospital, Southern Medical University
Phase 2/3BB

View all 50 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →